Licensing PARP Inhibitor A Win For BioMarin, Medivation
Executive Summary
BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.
You may also be interested in...
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.
Earnings Bleak, BioMarin Scrambles To In-License
Kuvan-launch mistakes and the Riquent fizzle take their toll, as company shops for workable assets.
Biopharma: Beyond the First Product
For biopharma, launching first products, and especially sudden profitability, doesn't necessarily predict which companies will succeed. Instead, an examination of stock market success shows the need to bring a succession of drugs, or at least additional indications, into clinical trials-mostly through aggressive deal-making.